Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q4 2022 Results Conference Call March 2, 2023 8:30 AM ET
Company Participants
Nareg Sagherian - Executive Director, Investor Relations
Jerry Durso - President and Chief Executive Officer
Linda Richardson - Chief Commercial Officer
Dr. Michelle Berrey - President, Research & Development and Chief Medical Officer
Andrew Saik - Chief Financial Officer
Conference Call Participants
Ritu Baral - Cowen
Mayank Mamtani - B. Riley Securities
Jon Wolleben - JMP Securities
Joseph Stringer - Needham & Company
Brian Skorney - Baird
Brian Abrams - RBC Capital Markets
Jay Olson - Oppenheimer
Eliana Merle - UBS
Operator
Good day and thank you for standing by. Welcome to the Intercept Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Nareg Sagherian, Executive Director, Investor Relations. Please go ahead.
Nareg Sagherian
Thank you. Good morning and thank you for joining us on today's call. This morning, we issued a press release announcing our fourth quarter and full year 2022 results, which is available on our website at intercept pharma.com.
Before we begin our discussion, I'd like to note that during our call, we will be making forward-looking statements, including statements regarding our approved product and clinical development program, certain regulatory matters and our strategy, prospects, financial guidance and future commercial and financial performance.
Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this call, and we undertake no obligation to update such statements, except as required by law.
These forward-looking statements are based on estimates and assumptions that, although believed to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.
Some, but not necessarily all of the risk factor that could cause our actual results to differ materially from our historical results or those anticipated or predicted by our forward-looking statements are discussed in this morning's press release and in our periodic public filings with the SEC.
Today's call will begin with prepared remarks from our President and CEO, Jerry Durso; our Chief Commercial Officer, Linda Richardson; President of Research and Development and Chief Medical Officer, Dr. Michelle Berry; and Chief Financial Officer, Andrew Saik. We will then open the call for questions.